The cell and gene therapy infrastructure and delivery models market focuses on the systems and models supporting CGT delivery from centralized GMP facilities to point-of-care manufacturing, cold-chain logistics, and clinic integration. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
7.1. Cell and Gene Therapy (CGT) Infrastructure & Delivery Models Market, by Therapy Type
7.1.1. Cell Therapy
7.1.1.1. Market Revenue and Forecast
7.1.2. Gene Therapy
7.1.2.1. Market Revenue and Forecast
7.1.3. Gene-Modified Cell Therapy (e.g., CAR-T)
7.1.3.1. Market Revenue and Forecast
8.1. Cell and Gene Therapy (CGT) Infrastructure & Delivery Models Market, by Delivery Mode
8.1.1. Centralized Manufacturing & Delivery
8.1.1.1. Market Revenue and Forecast
8.1.2. Decentralized/Point-of-Care Manufacturing
8.1.2.1. Market Revenue and Forecast
8.1.3. Hybrid Models
8.1.3.1. Market Revenue and Forecast
9.1. Cell and Gene Therapy (CGT) Infrastructure & Delivery Models Market, by Infrastructure Component
9.1.1. Manufacturing Facilities
9.1.1.1. Market Revenue and Forecast
9.1.2. Cold Chain Logistics
9.1.2.1. Market Revenue and Forecast
9.1.3. Supply Chain Orchestration Platforms
9.1.3.1. Market Revenue and Forecast
9.1.4. Cryopreservation Solutions
9.1.4.1. Market Revenue and Forecast
9.1.5. Clinical Site Infrastructure
9.1.5.1. Market Revenue and Forecast
9.1.6. Data Management & IT Infrastructure
9.1.6.1. Market Revenue and Forecast
10.1. Cell and Gene Therapy (CGT) Infrastructure & Delivery Models Market, by End-Use
10.1.1. Academic & Research Institutes
10.1.1.1. Market Revenue and Forecast
10.1.2. Hospitals & Transplant Centers
10.1.2.1. Market Revenue and Forecast
10.1.3. Commercial Treatment Centers (Private)
10.1.3.1. Market Revenue and Forecast
10.1.4. Biotech/Biopharma Companies
10.1.4.1. Market Revenue and Forecast
11.1. Cell and Gene Therapy (CGT) Infrastructure & Delivery Models Market, by Application Stage
11.1.1. Preclinical
11.1.1.1. Market Revenue and Forecast
11.1.2. Clinical (Phase I–III)
11.1.2.1. Market Revenue and Forecast
11.1.3. Commercial
11.1.3.1. Market Revenue and Forecast
12.1. Cell and Gene Therapy (CGT) Infrastructure & Delivery Models Market, by Service Provider
12.1.1. CDMOs (for CGT-specific infrastructure)
12.1.1.1. Market Revenue and Forecast
12.1.2. Specialty Logistics Providers
12.1.2.1. Market Revenue and Forecast
12.1.3. Clinical Site Network Providers
12.1.3.1. Market Revenue and Forecast
12.1.4. Digital Platform Providers (CGT workflow automation)
12.1.4.1. Market Revenue and Forecast
13.1. Cell and Gene Therapy (CGT) Infrastructure & Delivery Models Market, by Others
13.1.1. Closed-loop Processing Systems
13.1.1.1. Market Revenue and Forecast
13.1.2. Point-of-Care Manufacturing Platforms
13.1.2.1. Market Revenue and Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Therapy Type
14.1.2. Market Revenue and Forecast, by Delivery Mode
14.1.3. Market Revenue and Forecast, by Infrastructure Component
14.1.4. Market Revenue and Forecast, by End-Use
14.1.5. Market Revenue and Forecast, by Application Stage
14.1.6. Market Revenue and Forecast, by Others
14.1.7. Market Revenue and Forecast, by Service Provider
14.1.8. U.S.
14.1.8.1. Market Revenue and Forecast, by Therapy Type
14.1.8.2. Market Revenue and Forecast, by Delivery Mode
14.1.8.3. Market Revenue and Forecast, by Infrastructure Component
14.1.8.4. Market Revenue and Forecast, by End-Use
14.1.8.5. Market Revenue and Forecast, by Application Stage
14.1.8.6. Market Revenue and Forecast, by Others
14.1.8.7. Market Revenue and Forecast, by Service Provider
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Therapy Type
14.1.9.2. Market Revenue and Forecast, by Delivery Mode
14.1.9.3. Market Revenue and Forecast, by Infrastructure Component
14.1.9.4. Market Revenue and Forecast, by End-Use
14.1.9.5. Market Revenue and Forecast, by Application Stage
14.1.9.6. Market Revenue and Forecast, by Others
14.1.9.7. Market Revenue and Forecast, by Service Provider
14.2. Europe
14.2.1. Market Revenue and Forecast, by Therapy Type
14.2.2. Market Revenue and Forecast, by Delivery Mode
14.2.3. Market Revenue and Forecast, by Infrastructure Component
14.2.4. Market Revenue and Forecast, by End-Use
14.2.5. Market Revenue and Forecast, by Application Stage
14.2.6. Market Revenue and Forecast, by Others
14.2.7. Market Revenue and Forecast, by Service Provider
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Therapy Type
14.2.8.2. Market Revenue and Forecast, by Delivery Mode
14.2.8.3. Market Revenue and Forecast, by Infrastructure Component
14.2.8.4. Market Revenue and Forecast, by End-Use
14.2.8.5. Market Revenue and Forecast, by Application Stage
14.2.8.6. Market Revenue and Forecast, by Others
14.2.8.7. Market Revenue and Forecast, by Service Provider
14.2.9. Germany
14.2.9.1. Market Revenue and Forecast, by Therapy Type
14.2.9.2. Market Revenue and Forecast, by Delivery Mode
14.2.9.3. Market Revenue and Forecast, by Infrastructure Component
14.2.9.4. Market Revenue and Forecast, by End-Use
14.2.9.5. Market Revenue and Forecast, by Application Stage
14.2.9.6. Market Revenue and Forecast, by Others
14.2.9.7. Market Revenue and Forecast, by Service Provider
14.2.10. France
14.2.10.1. Market Revenue and Forecast, by Therapy Type
14.2.10.2. Market Revenue and Forecast, by Delivery Mode
14.2.10.3. Market Revenue and Forecast, by Infrastructure Component
14.2.10.4. Market Revenue and Forecast, by End-Use
14.2.10.5. Market Revenue and Forecast, by Application Stage
14.2.10.6. Market Revenue and Forecast, by Others
14.2.10.7. Market Revenue and Forecast, by Service Provider
14.2.11. Rest of Europe
14.2.11.1. Market Revenue and Forecast, by Therapy Type
14.2.11.2. Market Revenue and Forecast, by Delivery Mode
14.2.11.3. Market Revenue and Forecast, by Infrastructure Component
14.2.11.4. Market Revenue and Forecast, by End-Use
14.2.11.5. Market Revenue and Forecast, by Application Stage
14.2.11.6. Market Revenue and Forecast, by Others
14.2.11.7. Market Revenue and Forecast, by Service Provider
14.3. APAC
14.3.1. Market Revenue and Forecast, by Therapy Type
14.3.2. Market Revenue and Forecast, by Delivery Mode
14.3.3. Market Revenue and Forecast, by Infrastructure Component
14.3.4. Market Revenue and Forecast, by End-Use
14.3.5. Market Revenue and Forecast, by Application Stage
14.3.6. Market Revenue and Forecast, by Others
14.3.7. Market Revenue and Forecast, by Service Provider
14.3.8. India
14.3.8.1. Market Revenue and Forecast, by Therapy Type
14.3.8.2. Market Revenue and Forecast, by Delivery Mode
14.3.8.3. Market Revenue and Forecast, by Infrastructure Component
14.3.8.4. Market Revenue and Forecast, by End-Use
14.3.8.5. Market Revenue and Forecast, by Application Stage
14.3.8.6. Market Revenue and Forecast, by Others
14.3.8.7. Market Revenue and Forecast, by Service Provider
14.3.9. China
14.3.9.1. Market Revenue and Forecast, by Therapy Type
14.3.9.2. Market Revenue and Forecast, by Delivery Mode
14.3.9.3. Market Revenue and Forecast, by Infrastructure Component
14.3.9.4. Market Revenue and Forecast, by End-Use
14.3.9.5. Market Revenue and Forecast, by Application Stage
14.3.9.6. Market Revenue and Forecast, by Others
14.3.9.7. Market Revenue and Forecast, by Service Provider
14.3.10. Japan
14.3.10.1. Market Revenue and Forecast, by Therapy Type
14.3.10.2. Market Revenue and Forecast, by Delivery Mode
14.3.10.3. Market Revenue and Forecast, by Infrastructure Component
14.3.10.4. Market Revenue and Forecast, by End-Use
14.3.10.5. Market Revenue and Forecast, by Application Stage
14.3.10.6. Market Revenue and Forecast, by Others
14.3.10.7. Market Revenue and Forecast, by Service Provider
14.3.11. Rest of APAC
14.3.11.1. Market Revenue and Forecast, by Therapy Type
14.3.11.2. Market Revenue and Forecast, by Delivery Mode
14.3.11.3. Market Revenue and Forecast, by Infrastructure Component
14.3.11.4. Market Revenue and Forecast, by End-Use
14.3.11.5. Market Revenue and Forecast, by Application Stage
14.3.11.6. Market Revenue and Forecast, by Others
14.3.11.7. Market Revenue and Forecast, by Service Provider
14.4. MEA
14.4.1. Market Revenue and Forecast, by Therapy Type
14.4.2. Market Revenue and Forecast, by Delivery Mode
14.4.3. Market Revenue and Forecast, by Infrastructure Component
14.4.4. Market Revenue and Forecast, by End-Use
14.4.5. Market Revenue and Forecast, by Application Stage
14.4.6. Market Revenue and Forecast, by Others
14.4.7. Market Revenue and Forecast, by Service Provider
14.4.8. GCC
14.4.8.1. Market Revenue and Forecast, by Therapy Type
14.4.8.2. Market Revenue and Forecast, by Delivery Mode
14.4.8.3. Market Revenue and Forecast, by Infrastructure Component
14.4.8.4. Market Revenue and Forecast, by End-Use
14.4.8.5. Market Revenue and Forecast, by Application Stage
14.4.8.6. Market Revenue and Forecast, by Others
14.4.8.7. Market Revenue and Forecast, by Service Provider
14.4.9. North Africa
14.4.9.1. Market Revenue and Forecast, by Therapy Type
14.4.9.2. Market Revenue and Forecast, by Delivery Mode
14.4.9.3. Market Revenue and Forecast, by Infrastructure Component
14.4.9.4. Market Revenue and Forecast, by End-Use
14.4.9.5. Market Revenue and Forecast, by Application Stage
14.4.9.6. Market Revenue and Forecast, by Others
14.4.9.7. Market Revenue and Forecast, by Service Provider
14.4.10. South Africa
14.4.10.1. Market Revenue and Forecast, by Therapy Type
14.4.10.2. Market Revenue and Forecast, by Delivery Mode
14.4.10.3. Market Revenue and Forecast, by Infrastructure Component
14.4.10.4. Market Revenue and Forecast, by End-Use
14.4.10.5. Market Revenue and Forecast, by Application Stage
14.4.10.6. Market Revenue and Forecast, by Others
14.4.10.7. Market Revenue and Forecast, by Service Provider
14.4.11. Rest of MEA
14.4.11.1. Market Revenue and Forecast, by Therapy Type
14.4.11.2. Market Revenue and Forecast, by Delivery Mode
14.4.11.3. Market Revenue and Forecast, by Infrastructure Component
14.4.11.4. Market Revenue and Forecast, by End-Use
14.4.11.5. Market Revenue and Forecast, by Application Stage
14.4.11.6. Market Revenue and Forecast, by Others
14.4.11.7. Market Revenue and Forecast, by Service Provider
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Therapy Type
14.5.2. Market Revenue and Forecast, by Delivery Mode
14.5.3. Market Revenue and Forecast, by Infrastructure Component
14.5.4. Market Revenue and Forecast, by End-Use
14.5.5. Market Revenue and Forecast, by Application Stage
14.5.6. Market Revenue and Forecast, by Others
14.5.7. Market Revenue and Forecast, by Service Provider
14.5.8. Brazil
14.5.8.1. Market Revenue and Forecast, by Therapy Type
14.5.8.2. Market Revenue and Forecast, by Delivery Mode
14.5.8.3. Market Revenue and Forecast, by Infrastructure Component
14.5.8.4. Market Revenue and Forecast, by End-Use
14.5.8.5. Market Revenue and Forecast, by Application Stage
14.5.8.6. Market Revenue and Forecast, by Others
14.5.8.7. Market Revenue and Forecast, by Service Provider
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Therapy Type
14.5.9.2. Market Revenue and Forecast, by Delivery Mode
14.5.9.3. Market Revenue and Forecast, by Infrastructure Component
14.5.9.4. Market Revenue and Forecast, by End-Use
14.5.9.5. Market Revenue and Forecast, by Application Stage
14.5.9.6. Market Revenue and Forecast, by Others
14.5.9.7. Market Revenue and Forecast, by Service Provider
15.1. Catalent Cell & Gene Therapy
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Lonza
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. WuXi Advanced Therapies
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Thermo Fisher Scientific
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Charles River Laboratories
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. BioLife Solutions
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. TrakCel
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Vineti
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Cryoport Systems
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Be The Match BioTherapies
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description